OncLive TV

Adam D. Cohen, MD, discusses the efficacy of ciltacabtagene autoleucel in patients with lenalidomide-refractory multiple myeloma.

Noopur Raje, MD, discusses the utilization of bb21217 in patients with relapsed/refractory in multiple myeloma.

Paul G. Richardson, MD, discusses the overall survival benefit displayed by isatuximab plus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma.

Borja Puertas‐Martinez, MD, discusses the use of carfilzomib and dexamethasone with or without cyclophosphamide in patients with relapsed/refractory multiple myeloma.

Romanos Sklavenitis-Pistofidis, MD, discusses single-cell dissection of bone marrow and peripheral blood immune cells in smoldering multiple myeloma.

Mattia D'Agostino, MD, discusses factors that could lead to unsustained minimal residual disease negativity in patients with newly diagnosed multiple myeloma who are transplant eligible.

Shirish M. Gadgeel, MD, discusses the efficacy of adagrasib in patients with KRAS G12C–mutated non–small cell lung cancer and central nervous system metastases.

Matthew A. Lunning, DO, FACP, discusses the evolution of BTK inhibitors in chronic lymphocytic leukemia.

Howard M. Ross, MD, discusses the role of the microbiome colorectal cancer.

Neil Desai, MD, discusses the ideal patient for bladder preservation in urothelial cancer.

Eric Jonasch, MD, discusses the best patient population when treating with belzutifan in clear cell renal cell carcinoma.

Neil Desai, MD, discusses the evolving standard of care in urothelial cancer.

Peter Kozuch, MD, discusses the role of circulating tumor DNA in colorectal cancer.

Joyce A. O’Shaughnessy, MD, discusses the sequencing of pembrolizumab with chemotherapy in patients with early-stage triple-negative breast cancer.

Selina M. Luger, MD, FRCPC; Gail J. Roboz, MD; and Wendy Stock, MD, discuss how they turned their leukemia career “lemons” into “lemonade.”

Kathryn E. Beckermann, MD, PhD, discusses the evolving adjuvant treatment setting for renal cell carcinoma.

Anthony Mato, MD, MSCE, discusses the factors used to make treatment decisions between BTK inhibitors and venetoclax in chronic lymphocytic leukemia.

Jacqueline S. Garcia, MD, discusses the role of ruxolitinib (Jakafi) in myelofibrosis.

Benjamin Levy, MD, discusses the significance of the FDA approval of fam-trastuzumab deruxtecan-nxki in HER2-mutant non–small cell lung cancer.

Toni Choueiri, MD, discusses the future examination of adjuvant pembrolizumab in renal cell carcinoma.

Elise Nassif, MD, discusses examining gut microbial signatures in the tumor microenvironment.

Georgina V. Long, BSc, PhD, MBBS, FRACP, discusses evaluating pembrolizumab vs placebo in stage IIB or IIC melanoma.

Selina M. Luger, MD, FRCPC; Gail J. Roboz, MD; and Wendy Stock, MD, discuss what motivated them to continue working toward improvements in the leukemia field, even when outcomes were dismal and treatment options were scarce.

David Zhen, MD, discusses future research efforts in poorly differentiated small cell neuroendocrine carcinomas.

Amir Goldkorn, MD, discusses the methods utilized to predict chemotherapy benefit in bladder cancer.

Neel S. Bhatt, MBBS, MPH, discusses the longitudinal effects of chronic diseases in childhood cancer survivors.

Selina M. Luger, MD, FRCPC; Gail J. Roboz, MD; and Wendy Stock, MD, discuss the challenges that accompanied the lack of progress in leukemia treatment when they began their fellowships and express their excitement about encouraging developments that have since emerged in the arena.

Andrew Ip, MD, discusses the use of targeted next-generation sequencing in detecting chromosomal structural abnormalities in patients with myeloid neoplasms.

Saad Z. Usmani, MD, MBA, FACP, discusses the rapidly evolving treatment landscape in multiple myeloma.

Yi Lin, MD, PhD, discusses patient eligibility for CAR T-cell therapy in hematologic cancers.